MONUMENTAL-3 Data Support Talquetamab Plus Daratumumab ± Pomalidomide as a New SOC in R/R Myeloma – OncLive

Data from the MONUMENTAL-3 trial indicate that a combination of talquetamab and daratumumab, with or without pomalidomide, reduces the risk of mortality by up to 53% in patients with relapsed or refractory (R/R) multiple myeloma. According to reports from Seeking Alpha and MedPage Today, these results support the regimen’s potential as a new standard of care (SOC) for patients in earlier lines of treatment.

What are the primary outcomes of the MONUMENTAL-3 trial?

The MONUMENTAL-3 trial evaluated the efficacy of talquetamab (Talvey) combined with daratumumab (Darzalex Faspro) and the optional addition of pomalidomide. Seeking Alpha reports that this therapeutic approach cut the mortality risk by as much as 53% in late-stage trial participants. This figure represents a significant shift in survival outcomes for patients who have failed previous therapies.

MedPage Today notes that the talquetamab-based regimens specifically boosted overall survival in multiple myeloma patients. The data suggest that combining a bispecific antibody with existing standard treatments creates a more potent response than using these agents in isolation or in older sequences. This suggests the combination may prevent the rapid disease progression often seen in relapsed cases.

Key data points from the reported results include:

• Mortality Risk: Reduced by up to 53% according to Seeking Alpha.
• Patient Population: Relapsed or refractory (R/R) multiple myeloma.
• Primary Regimen: Talquetamab plus Daratumumab, with pomalidomide as an optional third agent.
• Clinical Goal: Establishing a new standard of care (SOC) for earlier-line R/R myeloma.

How does the Talvey and Darzalex Faspro combination work?

The combination leverages two different mechanisms to attack malignant plasma cells. Talquetamab is a bispecific antibody that targets GPRC5D, a protein highly expressed on the surface of myeloma cells. It acts as a bridge, pulling T-cells toward the cancer cells to trigger cell death. According to the Investing News Network, the strength of this bispecific combination is particularly evident when moved into earlier-line settings for relapsed or refractory patients.

Daratumumab targets CD38, another protein common on myeloma cells. By combining these two targets—GPRC5D and CD38—the treatment prevents the cancer from escaping through a single mutation or “escape pathway.” When pomalidomide, an immunomodulatory drug (IMiD), is added, it further enhances the immune response and inhibits the growth of the myeloma cells.

The Investing News Network emphasizes that this multi-pronged attack demonstrates a “strength” in earlier-line R/R myeloma, suggesting that treating patients before they become heavily pre-treated yields better survival outcomes.

Why is MONUMENTAL-3 significant for the Standard of Care (SOC)?

For years, the standard of care for relapsed or refractory multiple myeloma involved cycling through proteasome inhibitors, IMiDs, and anti-CD38 antibodies. However, many patients eventually develop resistance to these classes. The MONUMENTAL-3 data support talquetamab plus daratumumab ± pomalidomide as a new SOC because it introduces a new target (GPRC5D) into the treatment sequence earlier than previously practiced.

According to reports on MONUMENTAL-3 Data Support Talquetamab Plus Daratumumab ± Pomalidomide as a New SOC in R/R Myeloma – OncLive, the goal is to shift these high-efficacy bispecifics from “last-resort” therapies to earlier lines of treatment. This shift is intended to extend the period of progression-free survival and improve the quality of life before the disease becomes completely refractory to all known agents.

The implications for clinical practice include:

• Earlier Intervention: Using bispecifics like Talvey before patients fail five or more prior lines of therapy.
• Combination Synergy: Moving away from monotherapy toward “cocktails” that target multiple proteins simultaneously.
• Improved Survival: Reducing the mortality risk by half suggests a fundamental change in the prognosis for R/R patients.

What are the expert reactions to the trial data?

Medical professionals are monitoring the full rollout of these findings. Mark Wildgust, as reported by Oncodaily, expressed excitement regarding the presentation of the Monumental-3 data during the EHA 2026 meeting. The anticipation surrounding this presentation suggests that the oncology community views these results as a potential catalyst for changing prescribing guidelines.

The focus of the upcoming EHA 2026 discussions is expected to be the durability of the response. While the mortality risk reduction is a headline figure, clinicians want to see how long patients remain in remission and the toxicity profile of adding pomalidomide to the bispecific combination. The consensus among reported views is that the “strength” of the combination justifies its investigation as a frontline R/R option.

“Excited to see the Monumental3 data being presented during EHA2026 meeting.” — Mark Wildgust via Oncodaily.

How does this compare to previous myeloma treatments?

Historically, R/R myeloma treatment was a sequence of “salvage” therapies. Patients would receive a drug, achieve a response, relapse, and then move to the next available class. The MONUMENTAL-3 approach differs by utilizing a combination of a bispecific and a monoclonal antibody from the start of the relapsed phase.

While prior treatments often focused on a single target (like CD38), the talquetamab plus daratumumab regimen attacks two targets. Seeking Alpha’s report of a 53% mortality risk reduction is a stark contrast to the marginal gains often seen when simply switching from one IMiD to another in late-stage disease. This suggests that GPRC5D-targeted therapy provides a distinct advantage that does not overlap with the mechanisms of older SOC drugs.

Furthermore, the addition of pomalidomide allows for a customizable approach. Depending on the patient’s tolerance for side effects, physicians can choose the doublet (Talvey + Darzalex) or the triplet (Talvey + Darzalex + Pomalidomide), providing a flexibility not found in many previous fixed-dose trials.

What are the potential challenges and side effects?

Despite the survival benefits, bispecific antibodies like talquetamab are associated with specific risks. The most notable is Cytokine Release Syndrome (CRS), an overactivation of the immune system that can cause fever, low blood pressure, and organ failure. While the MONUMENTAL-3 data support the efficacy of the regimen, the management of CRS remains a critical part of the administration process.

Additionally, talquetamab can cause skin toxicity and taste disturbances (dysgeusia), which can impact the quality of life. The addition of pomalidomide introduces further risks, such as venous thromboembolism (blood clots) and neutropenia. Clinicians must balance the 53% reduction in mortality risk against these potential adverse events.

To mitigate these risks, the trial protocols often involve:

• Step-up Dosing: Gradually increasing the dose of talquetamab to reduce the severity of CRS.
• Prophylactic Treatment: Using corticosteroids or other agents to manage inflammation.
• Close Monitoring: Intensive observation during the first few doses of the bispecific agent.

Timeline of Development and Key Milestones

The path to the MONUMENTAL-3 results involved several years of targeted research into GPRC5D. The development of talquetamab represented a breakthrough in identifying a target that was as consistently expressed as CD38 but remained untapped by previous drugs.

Understanding the Impact on Patient Access

If the MONUMENTAL-3 data lead to a formal change in the standard of care, it will likely increase the demand for bispecific antibodies in earlier stages of the disease. This could put pressure on healthcare systems and insurance providers due to the high cost of these biologics. However, the argument for earlier use is based on the “value” of survival; a 53% reduction in mortality risk is a powerful metric for justifying the cost of therapy.

Patients who previously would have waited until they were “triple-class refractory” (resistant to proteasome inhibitors, IMiDs, and anti-CD38s) may now receive these combinations much sooner. This change in sequence could potentially eliminate the need for several subsequent, less effective lines of therapy, potentially streamlining the treatment journey for those with R/R myeloma.

For those interested in how these drugs are administered, a related explainer on bispecific antibody administration provides more detail on the clinical setting required for these treatments.

Frequently Asked Questions

What is the MONUMENTAL-3 trial?

MONUMENTAL-3 is a clinical trial evaluating the combination of talquetamab (Talvey) and daratumumab (Darzalex Faspro), with or without pomalidomide, for patients with relapsed or refractory multiple myeloma. The trial aims to determine if this combination can serve as a new standard of care by improving survival rates.

How much did the mortality risk decrease in the trial?

According to data reported by Seeking Alpha, the mortality risk for patients in the trial was reduced by up to 53% when using the talquetamab-based combination therapy.

What makes talquetamab different from other myeloma drugs?

Talquetamab is a bispecific antibody that targets GPRC5D. Unlike daratumumab, which targets CD38, talquetamab uses a different protein on the surface of the cancer cell to attract T-cells, allowing it to work even in patients who have become resistant to CD38-targeted therapies.

When will the full data be presented?

As reported by Oncodaily and noted by Mark Wildgust, the detailed data from the MONUMENTAL-3 trial are expected to be presented during the EHA 2026 meeting.

Is pomalidomide required for this treatment to work?

No. The trial tested the combination both with and without pomalidomide (± Pomalidomide). While the addition of pomalidomide can enhance the response, the core efficacy is driven by the combination of talquetamab and daratumumab.

The findings from MONUMENTAL-3 suggest a shift toward more aggressive, multi-targeted combinations earlier in the treatment of relapsed multiple myeloma. By reducing mortality risk by over half, the regimen of talquetamab and daratumumab positions itself as a formidable alternative to previous sequential therapy models. As the medical community awaits the full presentation at EHA 2026, the focus remains on the potential for this combination to redefine the survival expectations for thousands of patients worldwide.